Last reviewed · How we verify
prolotherapy solution of 20% dextrose — Competitive Intelligence Brief
marketed
Regenerative medicine agent
Orthopedics / Musculoskeletal
Small molecule
Live · refreshed every 30 min
Target snapshot
prolotherapy solution of 20% dextrose (prolotherapy solution of 20% dextrose) — Hadassah Medical Organization. A 20% dextrose solution injected into damaged connective tissues stimulates a local inflammatory response that promotes tissue repair and regeneration.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| prolotherapy solution of 20% dextrose TARGET | prolotherapy solution of 20% dextrose | Hadassah Medical Organization | marketed | Regenerative medicine agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Regenerative medicine agent class)
- Hadassah Medical Organization · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- prolotherapy solution of 20% dextrose CI watch — RSS
- prolotherapy solution of 20% dextrose CI watch — Atom
- prolotherapy solution of 20% dextrose CI watch — JSON
- prolotherapy solution of 20% dextrose alone — RSS
- Whole Regenerative medicine agent class — RSS
Cite this brief
Drug Landscape (2026). prolotherapy solution of 20% dextrose — Competitive Intelligence Brief. https://druglandscape.com/ci/prolotherapy-solution-of-20-dextrose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab